Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Emily Shelley

Dermatology Indianapolis, IN Doctor of Osteopathy

NPI 1467834127 CMS profile 1402022

8433 Harcourt Rd Ste 310, Indianapolis, IN 46260

Open in the dashboard

General payments

$8,743

512 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Emily Shelley of Indianapolis, IN is reported in the CMS Open Payments database as having received $8,743 across 512 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,133 55
2024 General $1,357 85
2023 General $2,076 123
2022 General $988 58
2021 General $1,174 83
2020 General $774 52
2019 General $1,241 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Emily Shelley
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Emily Shelley were reported at $1,133. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Emily Shelley Dermatology median Middle half National median
2019 $1,241 $454 $129–$1,240 $163
2020 $774 $235 $81–$756 $114
2021 $1,174 $377 $108–$1,108 $132
2022 $988 $514 $143–$1,391 $149
2023 $2,076 $607 $159–$1,674 $160
2024 $1,357 $751 $204–$1,903 $164
2025 $1,133 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,522 81 payments
  2. Sun Pharmaceutical Industries Inc. $1,143 71 payments
  3. Pfizer Inc. $891 57 payments
  4. Novartis Pharmaceuticals Corporation $797 78 payments
  5. Genzyme Corporation $597 28 payments
  6. Lilly USA, LLC $460 23 payments
  7. Galderma Laboratories, L.P. $449 20 payments
  8. Janssen Biotech, Inc. $400 17 payments
  9. E.R. Squibb & Sons, L.L.C. $289 21 payments
  10. LEO Pharma Inc. $264 13 payments
  11. Other $1,929 103 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,431 508 payments
  2. Education $312 4 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT $753 35 payments
  2. SKYRIZI $741 42 payments
  3. ILUMYA $710 52 payments
  4. EUCRISA $696 46 payments
  5. HUMIRA $695 29 payments
  6. CIBINQO $574 38 payments
  7. TALTZ $460 23 payments
  8. LITFULO $443 28 payments
  9. TREMFYA $400 17 payments
  10. COSENTYX $328 36 payments
  11. Other $4,902 299 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

592

Median for Dermatology: 534

Drug cost

$96,592

Median for Dermatology: $67,151

Branded share of claims

9.8%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 23 $85,216
Betamethasone Dipropionate Generic 54 $1,702
Doxycycline Hyclate Generic 46 $1,320
Imiquimod Generic 29 $1,208
Clobetasol Propionate Generic 26 $1,170
Ketoconazole Generic 67 $964
Metronidazole Generic 19 $936
Fluorouracil Generic 11 $911
Clindamycin Phosphate Generic 29 $808
Triamcinolone Acetonide Generic 114 $803

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $141
  • Regeneron Healthcare Solutions, Inc. $54
$195 23 —
ILUMYA
  • Sun Pharmaceutical Industries Inc. $189
$189 — —
SKYRIZI
  • AbbVie, Inc. $111
$111 — —
VTAMA
  • Dermavant Sciences, Inc. $104
$104 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $92
$92 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

512 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record